Cargando…

Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer

The activity of the following drugs was investigated in two established NSCLC cell lines: docetaxel, gemcitabine, vinorelbine, paclitaxel, doxorubicin (0.01, 0.1, 1 μg ml(−1)), cisplatin, ifosfamide (1, 2, 3 μg ml(−1)) and carboplatin (2, 4, 6 μg ml(−1)). The cytotoxic activity was evaluated by the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zoli, W, Ricotti, L, Susino, M Dal, Barzanti, F, Frassineti, G L, Folli, S, Tesei, A, Bacci, F, Amadori, D
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362882/ https://www.ncbi.nlm.nih.gov/pubmed/10574245 http://dx.doi.org/10.1038/sj.bjc.6690737

Ejemplares similares

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
por: Passardi, Alessandro, et al.
Publicado: (2008)

Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line
por: Fabbri, Francesco, et al.
Publicado: (2008)

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
por: Passardi, Alessandro, et al.
Publicado: (2006)

Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines
por: Zoli, Wainer, et al.
Publicado: (2005)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)
por: Baldini, E, et al.
Publicado: (2001)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines
por: Lopez-Acevedo, Micael, et al.
Publicado: (2014)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
por: Moorsel, C J A van, et al.
Publicado: (1999)

Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study
por: Ardavanis, A, et al.
Publicado: (2005)

Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines
por: Tesei, Anna, et al.
Publicado: (2007)

In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines
por: Tesei, Anna, et al.
Publicado: (2005)

Docetaxel/gemcitabine: Various toxicities: 4 case reports
Publicado: (2021)

Retrospective evaluation of the role of gemcitabine‐docetaxel in well‐differentiated and dedifferentiated liposarcoma
por: Thirasastr, Prapassorn, et al.
Publicado: (2022)

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study
por: Gunelli, R, et al.
Publicado: (2007)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

Short Interfering RNA Directed against the SLUG Gene Increases Cell Death Induction in Human Melanoma Cell Lines Exposed to Cisplatin and Fotemustine
por: Vannini, Ivan, et al.
Publicado: (2007)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
por: Joensuu, H., et al.
Publicado: (2010)

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
por: Palmerini, E., et al.
Publicado: (2016)

Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC
por: Ulivi, Paola, et al.
Publicado: (2013)

A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma
por: Seddon, Beatrice, et al.
Publicado: (2015)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

DT-diaphorase activity in NSCLC and SCLC cell lines: a role for fos/jun regulation
por: Kepa, J K, et al.
Publicado: (1999)

The effect of docetaxel on retinal pigment epithelial cells
por: Li, Jialin, et al.
Publicado: (2022)

Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis
por: Ulivi, Paola, et al.
Publicado: (2013)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
por: Xu, Jie, et al.
Publicado: (2018)

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
por: Pender, Alexandra, et al.
Publicado: (2018)

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
por: Wang, G-S, et al.
Publicado: (2001)

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes
por: Qi, Guoyan, et al.
Publicado: (2017)

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
por: Kroep, J R, et al.
Publicado: (2000)

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study
por: Douillard, J Y, et al.
Publicado: (2001)

Complete Remission of Recurrent Retroperitoneal Liposarcoma after the Administration of Gemcitabine and Docetaxel as First-Line Adjuvant Chemotherapy: A Case Report
por: Da Silva, Filipe Rocha, et al.
Publicado: (2018)

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
por: Lee, Ha-young, et al.
Publicado: (2012)

Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer
por: Li, Fenghu, et al.
Publicado: (2019)

Gemcitabine and Docetaxel Combination Chemotherapy Induced Dermatomyositis Associated with Hand-Foot Syndrome
por: Kawada, Mayuko, et al.
Publicado: (2021)

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease
por: Casadei Gardini, Andrea, et al.
Publicado: (2013)

Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
por: Gridelli, C, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_cv82um8q1ojhm31r4jdfmdvb1v